Performance of an Investigational Blood Glucose Monitoring System in a Clinical Trial
Clinical Trial Protocol for Contour Link System With Contour Sensor
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Indiana
-
Mishawaka, Indiana, United States, 46544
- Bayer HealthCare LLC, Diabetes Care
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females, 18 years of age and above
- Diagnosed as having type 1 or type 2 diabetes
- Currently self-testing blood glucose at home for at least three months
- Able to speak, read, and understand English
- Willing to complete all study procedures
Exclusion Criteria:
- Gestational Diabetes
- Hemophilia or any other bleeding disorder
- Employee of competitive medical device company
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intended Users of the System
Subjects with diabetes used Contour Link Investigational Blood Glucose Monitoring System
|
Subjects with diabetes and study staff each performed Blood Glucose tests from the subject's capillary blood obtained from fingerstick using the Contour Link investigational meter.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent of Fingerstick Blood Glucose (BG) Results Within +/-20%(>=75 mg/dL) and Within +/- 15mg/dL (<75 mg/dL) of Laboratory Glucose Method
Time Frame: 1 hour
|
Subjects with diabetes and study staff tested subject fingerstick blood using an investigational blood glucose meter (BGM).
BGM results were compared to a reference lab glucose method - Yellow Springs Instrument (YSI) Analyzer.
BG results were used to calculate the number of BG results within +/- 20% (for reference BG results >=75mg/dL) and within +/- 15mg/dL(for reference BG results <75mg/dL) of the reference method results.
|
1 hour
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Evaluation)
Time Frame: 1 hour
|
Subjects read User Guide(UG)to learn to use the system and performed meter tasks.
Study staff observed, then rated subjects' success (1 to 4) at performing tasks.
Scale: 1.Performed tasks correctly without assistance.
2.Performed tasks correctly, but was directed to a specific part of the UG by the study staff as in a Customer Service call.
3.Performed tasks correctly, but required additional review/assistance similar to review of a specific function during a Customer Service call.
4.Subject incorrectly performed part of the testing regimen and was unaware of the error.
|
1 hour
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- R&D-2010-2011.09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.